NCT01382277Unknown4 期
Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 600
- 试验地点
- 2
- 主要终点
- Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks
研究概览
简要总结
This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Men or women, aged 18 -75
- •Diagnosed with coronary heart disease (CHD) stable angina for more than 1 month and meet the following any one:
- •History of myocardial infarction.
- •CHD confirmed by coronary angiography.
- •Excercise ECG positive for CHD or perfusion defect
- •One or more main branch of coronary artery stenosis ≥ 50% confirmed by CT scanning.
- •Hyperlipidemia (lipid-lowering treatment naïve: LDL-C ≥130mg/dl, or having received lipid-lowering treatment: LDL-C ≥100mg/dl)
- •The 64 slice CT shows at least one significant coronary artery stenosis ≥20% with the narrowest ≤60% and meeting the following criteria:
- •Diameter of coronary artery lesion ≥2mm, length ≥5mm; distance between multiple lesions >1cm
- •Plaque density <100HU, no calcification
- •Vascular stenosis (20～60%) caused by plaques
- •Plaque thickness >1mm
- •Plaque not in the coronary artery with previous PCI treatment.
排除标准
- •Acute myocardial infarction within 6 months
- •PCI or CABG therapy within 6 months
- •Anticipated PCI or CABG therapy in the following 3 months.
- •Tropnin I/Tropnin T higher than ULN
- •Cardiac failure NYHA III or above
- •Coronary artery left main stenosis >50%
- •Emergency coronary angiography(CAG) is needed
- •Serious arrhythmia or tachycardia
- •Secondary hyperlipidemia
- •Familial hypercholestrolemia
- •Uncontrolled severe hypertension (≥200/110 mmHg)
- •Uncontrolled diabetes (HbA1c ≥9.5%)
- •Triglyceride ≥500 mg/dL (5.65 mmol/L)
- •Active hepatic disease or hepatic function impairment, ALT≥3ULN
- •Serum creatinine >177 µmol/L (2.0 mg/dL)
- •Myalgia or blood CK ≥5ULN
- •WBC < 4×10e9/L，or PLT < 100*10e9/L。
- •Participation in the the course of plan and/or procedure of this study
- •Previous participation in the study treatment
- •Participation in other clinical studies in the past 3 months
- •Pregnant or breast-feeding women, women with child-bearing potential who did not use drugs or devices for contraception, or women with positive urine pregnancy test (human chorionic gonadotropin [HCG])
- •History of malignant tumors (exception: recovered more than 10 years or only basal cell carcinoma or squamous cell carcinoma); females with a history of cervical atypical hyperplasia (exception: 3 consecutive cervical smear tests normal prior to enrolment)
- •History of alcohol and/or drug abuse in recent 5 years
- •Any serious or unstable physical or psychological conditions, in the opinion of the investigator, would compromise the safety of the patient or the participation in this study
- •Use of concomitant medications prohibited in this study ( Erythromycin, clarithromycin, erythromycin ethylsuccinate, sulfaphenazole; Fluconazole, ketoconazole, itraconazole; Niacin / nicotinic acid(including vitamins/food additives containing niacin / nicotinic acid >50mg), probucol, clofibrate, cholestyramine, colestipol hydrochloride, ezetimibe, fenofibrate, gemfibrozil, atorvastatin(exception: study medication)，lovastatin, pravastatin, rosuvastatin (exception: study medication) , Simvastatin, fluvastatin, fish oil (any dose), lipid-lowering supplements and food additives; Cyclosporine; Protease inhibitors)
- •Use of periodic hormone replacement treatment(HRT), oral contraceptives(OCTs), long-acting progesterone, or in recent 3 months non-periodic HRT or OCTs
- •Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
研究组 & 干预措施
Rosuvastatin 20 mg
Experimental
Rosuvastatin 20 mg for 76 weeks.
干预措施: Rosuvastatin (Drug)
结局指标
主要结局
Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks
时间窗: 76 weeks
次要结局
- Change from baseline in hsCRP at 26 weeks(26 weeks)
- Number of participants with adverse events and abnormal laboratory safety markers.(76 weeks)
- Change from baseline in Carotid intima-media thickness at 76 weeks(76 weeks)
- Change from baseline in blood lipids at 52 weeks(52 weeks)
- Change from baseline in hsCRP at 52 weeks(52 weeks)
- Change from baseline in hsCRP at 76 weeks(76 weeks)
- Change from baseline in blood lipids at 76 weeks(76 weeks)
- Change from baseline in blood lipids at 26 weeks(26 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)Coronary ArteriosclerosisNCT00240318AstraZeneca450
终止
4 期
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive PatientsAtherosclerosisHIV InfectionsNCT00673582University of British Columbia250
Unknown
4 期
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)AtherosclerosisHyperlipidemiaNCT00885872Chinese PLA General Hospital60
已完成
3 期
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)Renal FailureNCT00240331AstraZeneca2,776
Unknown
不适用
Peking and Rotterdam on Mission to Reduce Coronary Artery DiseaseDiabetes MellitusAcute Coronary SyndromeNCT01653119Peking University Third Hospital1,000